GLP-1RAs stimulate insulin secretion, decrease glucagon concentration, delay gastric emptying, and decrease appetite, making them an attractive therapy for both obesity and T2DM (43). The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.